{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036113","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.126246+00:00","generated_at":"2026-05-31T11:29:20.480050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead Q3 net loss $170.8M ($1.38/sh); secures $500M credit facility; plozasiran Phase 3 meets endpoints","bullets":["Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.","Secured $500M non-dilutive credit facility from Sixth Street ($400M funded, $100M available) plus $50M milestone from Royalty Pharma.","Pivotal Phase 3 PALISADE study of plozasiran in FCS met primary endpoint: triglycerides reduced up to 80%, APOC3 up to 94%, acute pancreatitis incidence reduced vs placebo.","Initiated Phase 3 SHASTA-3/4 for plozasiran in severe hypertriglyceridemia; plans for Phase 3 CAPITAN cardiovascular outcomes trial.","Cash and investments $436.7M at June 30, 2024, up from $403.6M at Sept 30, 2023; company approaching plozasiran launch in 2025 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036113","json":"https://secwatch.observer/filing/0001628280-24-036113.json","markdown":"https://secwatch.observer/filing/0001628280-24-036113.md","text":"https://secwatch.observer/filing/0001628280-24-036113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828024036113/0001628280-24-036113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828024036113/arwr-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:29:20.480050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}